Background {#Sec1}
==========

Coronavirus disease 2019 (COVID-19) is a respiratory illness caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 disease was first described in Wuhan, China in December 2019 and is now a global pandemic. As of the 12th of April 2020, there were 1,696,588 confirmed COVID-19 cases worldwide, 10--15% of which have severe disease and over 105,952 deaths reported \[[@CR1]\]. Most of those affected have milder illness (80%), 15% are severely ill (require oxygen) and 5% will require admission to the intensive care unit (ICU). The Clinical Blood Sciences Laboratory (CBSL) plays a key role in supporting the monitoring and management of COVID-19 disease. Routine CBSL tests recommended to support medical decision-making and prognostication based on the current literature are detailed in Table [1](#Tab1){ref-type="table"} \[[@CR2]\]. Recent evidence suggests that patients with severe COVID-19 are at risk for cytokine storm syndrome \[[@CR3]\] and that where possible, Interleukin 6 (IL-6) should be used to assess these patients for suspected hyperinflammation \[[@CR3], [@CR4]\]. Furthermore, elevated concentrations of procalcitonin (a peptide precursor of the hormone calcitonin) in the circulation is associated with \~ 5-fold higher risk of developing the severe form of the disease \[[@CR5]\].Table 1Clinical blood science testing for COVID-19 patients in hospitalParameterAbnormalityUtility for prognosticationBiochemistry  Inflammatory biomarkers    Interleukin 6↑+ VelocityHyperinflammatory syndrome    Procalcitonin↑+ VelocityBacterial (Super) infection  Acute phase proteins    C-reactive protein↑Inflammation/sepsis    Albumin↓Response to severe inflammation    Ferritin↑  Lung    pH↑Assessment of pulmonary functionCheck blood gases regularly (every 30 minutes if patient deteriorating)    Partial pressure of oxygen (pO~2~)↓    Partial pressure of carbon dioxide (pCO~2~)↓    Bicarbonate (HCO~3~)N/ ↑    Fraction of inspired oxygen (FIO~2~)↓    Lactate↑  Renal    Electrolytes (Na^+^/K^+^/CL^−^)↑Na^+^Insensible losses and diuretic therapyMay portend acute kidney injury    Urea↑Acute kidney injury (AKI)Cr increase 26 μmol/L/48 h; or 1.5× baseline/7 days    Creatinine (Cr)↑  Liver    Total bilirubin↑Liver injury    Alanine transaminase (ALT)↑    Aspartate aminotransferase (AST)↑    Lactate dehydrogenase (LDH)↑Tissue damage/multiple organ failure  Heart    High-sensitivity cardiac troponin↑Cardiac myositis/increased oxygen demand/inflammation    B-type natriuretic peptide↑Severity of inflammation/ventricular dysfunction  Other    Creatine phosphokinase (CPK)↑Muscle injury    Triglycerides↑Increased lipolysis    GlucoseN/↑Increased stress response    Ionized calcium↓RI/impaired PTH action/chelation precipitation    Phosphate↓Required for multiple enzyme function    Magnesium↓    Vitamin D (25(OH)D)↓Inflammatory response/decreased synthesisHaematology  Full blood count    White cell count (WCC)↑Response to bacterial infection    Neutrophils↑    Leucocytes↑    Lymphocytes↓Immunological response to COVID-19    PlateletsN/↓Counts fall consequent to consumption/DICCoagulation profile  D-dimers↑Activation of blood coagulationFibrinogen concentration falls in DIC or consumptive coagulopathy  Fibrinogen↑  Prothrombin time (PT)↑Immunology  Cytokine panel    IL-1ß, IL6, IL8, TNF-α↑Disease severity/cytokine storm syndrome*DIC* disseminated intravascular coagulopathy, *N* normal, *RI* renal impairment, *PTH* parathyroid hormone

Septic shock {#Sec2}
------------

Septic shock in adults is recognised when infection is suspected or confirmed, lactate is ≥ 2 mmol/L and vasopressors are needed to maintain a mean arterial pressure (MAP) of 60--65 mmHg in the absence of hypovolemia \[[@CR6]\].

Cytokine storm syndrome {#Sec3}
-----------------------

Inflammation is the body's first line of defence against infection, responding to challenges by activating innate and adaptive immune responses. Ironically, hyperinduction of proinflammatory cytokine production (cytokine storm syndrome) can put a patient at risk for complications associated with COVID-19. Early recognition of this possibility is required to inform management and treatment decisions. This is important as potential treatments with existing approved therapies with proven safety profiles such as tocilizumab (an IL-6 receptor blocker) and Janus kinase (JAK) inhibitors have been mooted to address the rising mortality in patients with COVID-19 pneumonia and elevated IL-6 \[[@CR3]\]. Identifying patients to direct these specific treatments is aided by measuring C-reactive protein (CRP), interleukin 6 (IL-6), ferritin and procalcitonin. IL-6 drives CRP and is an earlier marker of the status of a patients' inflammatory status. Elevated IL-6 concentrations together with the velocity of an increasing result portend an impending deterioration in clinical status.

Procalcitonin (PCT) is released into the circulation during bacterial infections and sustained by interleukins IL1-β, IL-6 and tumour necrosis factor alpha (TNF-α). PCT is inhibited by interferon gamma (IFN-γ), the primary activator of macrophages and stimulator of natural killer cells and neutrophils. Hence, PCT levels should remain within the reference interval in uncomplicated COVID-19 disease. Markedly abnormal PCT results on the other hand are consistent with bacterial coinfection in those developing severe forms of the disease \[[@CR5], [@CR7]--[@CR10]\].

Lung {#Sec4}
----

Angiotensin-converting enzyme 2 (ACE2) is the functional receptor for SARS-CoV-2. Human tissue studies have determined that ACE2 is expressed in some 15 organs, including the heart, kidneys and lung \[[@CR11]\]. ACE2 is a key counterregulatory enzyme of the renin-angiotensin-aldosterone system (RAAS) that degrades angiotensin II to angiotensin-(1--7) reducing its effects on vasoconstriction, sodium retention and blood pressure. SARS-CoV-2 has a predilection for type II epithelial cells of the alveoli, with the lower airways being the dominant site of injury in COVID-19 \[[@CR12]\]. The spectrum of COVID-19 lung illness spans asymptomatic infection and mild upper respiratory tract illness to severe viral pneumonia with respiratory failure and even death \[[@CR13]\]. Arterial/venous blood gas parameters (pH, pO~2~, pCO~2~, HCO~3~, FIO~2~ and lactate) are used to monitor the patients' respiratory function and inform clinical decision-making. Criteria used to evaluate the severity of COVID-19 disease are detailed in Table [2](#Tab2){ref-type="table"}.Table 2Criteria used to evaluate the severity of COVID-19 patients in hospitalCriterionIf any of the following 3 criteria are met or exceeded  Respiratory rate≥ 30 breaths/min  SpO~2~\< 93% while breathing room air  PaO~2~/FIO~2~≤ 300 mmHg/40 kPaA critical case is defined if in addition any of the following 3 criteria are met  Respiratory failureRequiring mechanical ventilation  ShockVasopressors required to maintain MAP, lactate ≥ 2 mmol/L and absence of hypovolaemia  Multiorgan failureOther organ failure (SOFA) and ICU admission*SpO*~*2*~ peripheral capillary oxygen saturation (estimate of the amount of oxygen in blood), *PaO*~*2*~ partial pressure of oxygen in arterial blood, *FIO*~*2*~: fraction of inspired oxygen, *MAP* mean arterial pressure (60--65 mmHg), *SOFA* sequential organ failure assessment

Kidney: acute kidney injury {#Sec5}
---------------------------

Acute kidney injury (AKI) requiring dialysis is reported in a subset of patients admitted to ICU. The exact mechanism is unclear at this point, but AKI is present in \~ 7% of patients with pathology demonstrating acute tubular necrosis. AKI correlates with an overall poor prognosis and seems to be the strongest predictor of mortality \[[@CR14]\].

Many factors can affect the metabolism of creatinine from creatine in muscles and the rate of secretion of creatinine in the renal tubules, influencing both creatinine measurements and estimates of glomerular filtration rate (eGFR), the best overall index of kidney function. The National Kidney Foundation recommends using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) formula for eGFR \[[@CR15]\]. However, the population used to derive this formula contained a limited number of elderly people and racial and ethnic minorities with measured GFR. Moreover, renal function in these patients is not in a steady state. Routine urine tests recommended to support medical decision-making are detailed in Table [3](#Tab3){ref-type="table"}.Table 3Clinical laboratory urine testing of COVID-19 patients in hospitalUrine parameterCriterion valueUtility for prognosticationUrine outputVolume \< 0.5 mL/kg/h for 6 hAKIOsmolality  True hyponatraemia:Serum Na^+^: \< 133 mmol/L\> 100 mOsm/kgEvidence of AVP action, from SIAD or baroregulated AVP release (hypotension/hypovolaemia)\< 100 mOsm/kgNormal water excretion  Spot urine Na^+^\< 30 mmol/L\> 30 mmol/L  HypovolaemicDepletion: GI/skin/mucosa/diureticsAddison's diseaseCSWS/SWN/diuretics  EuvolaemicHypothyroidismSIADH with fluid restrictionSIADHHypopituitarism  HypervolaemicCirrhosis CCFRenal impairment CCFDiureticsProteinuria  Albumin: creatinine ratio (ACR)\> 30 mg/mmolClassification: degree of renal impairment/target organ damage  Protein: creatinine ratio (PCR)\> 15 mg/mmol*AKI* acute kidney injury, *SIAD* syndrome of inappropriate antidiuresis, *GI* gastrointestinal, *AVP* arginine vasopressin, *CSWS* cerebral salt wasting syndrome, *SWN* salt wasting nephropathy, *CCF* congestive cardiac failure

Liver: hepatocyte injury and disseminated intravascular coagulopathy {#Sec6}
--------------------------------------------------------------------

Elevated liver chemistries (alanine transaminase (ALT) aspartate aminotransferase (AST)) in COVID-19 disease are indicative of hepatocyte injury. While increased concentrations of bilirubin, prothrombin (a vitamin K-dependent coagulation factor) and fibrinogen (a 340-kDa glycoprotein) synthesised in the liver are indicative of liver dysfunction. Prothrombin is proteolytically cleaved to form thrombin which converts fibrinogen to fibrin and then to a fibrin-based blood clot to occlude blood vessels and arrest bleeding. A D-dimer is a fibrin degradation product present in the blood after a blood clot is degraded by fibrinolysis. In acute sepsis, the coagulation system becomes diffusely activated with consumption of multiple clotting factors resulting in disseminated intravascular coagulopathy (DIC) \[[@CR16]\]. Pathogenesis is driven by an upregulation of procoagulant mechanisms and simultaneous downregulation of natural anticoagulants. The prevention of DIC in COVID-19 patients is critical to prevent multiorgan failure and efforts should centre on stratifying patients at high risk for DIC. The prothrombin test (PT) (which measures the time it takes blood to clot (Normally: 11--12.5 s)), fibrinogen, D-dimers and the platelet count are significant predictors of disease severity as test abnormalities herald the onset of DIC. Klok et al. report a 31% incidence of thrombotic complications in ICU patients with COVID-19 and reinforce the recommendation for strict adherence to thrombosis prophylaxis \[[@CR17]\].

Heart: myocardial injury, high-sensitivity cardiac troponin and B-type natriuretic peptide {#Sec7}
------------------------------------------------------------------------------------------

Clinical studies have demonstrated that patients with long-term coronary artery disease and those with risk factors for atherosclerotic cardiovascular disease (CVD) are at increased risk of developing an acute coronary syndrome during influenza \[[@CR18], [@CR19]\] and acute inflammatory infections \[[@CR20]\]. The speculated mechanism is that severe systemic inflammation leads to atherosclerotic plaque instability and rupture. Elevated high-sensitivity cardiac troponin concentrations are indicative of myocardial injury. Shi et al. reported that greater proportions of COVID-19 patients with cardiac injury required non-invasive mechanical ventilation (38 of 82 \[46.3%\] vs 13 of 334 \[3.9%\]; *P* \< 0.001) or invasive mechanical ventilation (18 of 82 \[22.0%\] vs 14 of 334 \[4.2%\]; *P* \< 0.001) when compared to those without cardiac injury \[[@CR21]\]. Further, that in this cohort, higher concentrations of high-sensitivity cardiac troponin were associated with higher mortality \[[@CR21]\]. Ruan et al. also reported that patients with CVD infected with SARS-CoV-2 had a significantly increased risk of death \[[@CR4]\]. These authors determined that some of their patients with SARS-CoV-2 died of fulminant myocarditis. Direct viral infection of the vascular epithelium and myocardium has been promulgated based on the unique affinity of SARS-CoV-2 for the host ACE2 receptor \[[@CR22]\]. Hence, raising the possibility of myocarditis occurring in some COVID-19 patients irrespective of existing or pre-existing CVD \[[@CR20], [@CR21], [@CR23]\].

Patients with heart failure are prone to haemodynamic decompensation and an unfavourable course when infected with SARS-CoV-2 \[[@CR24]\]. Recent insights have been provided by Guo et al. demonstrating that cardiac troponin levels are significantly associated with C-reactive protein (CRP) and B-type natriuretic peptide, linking myocardial injury to severity of inflammation during hospitalisation in patients who follow a deteriorating clinical course toward death \[[@CR25]\]. Patients with myocardial injury also have evidence of elevated leukocyte counts, CRP, procalcitonin (PCT) and creatinine phosphokinase (CPK).

Muscle {#Sec8}
------

Muscle breakdown as evidenced by raised levels of creatine phosphokinase (CPK) and myoglobin has been reported to occur in patients with COVID-19 disease \[[@CR4], [@CR9], [@CR13]\].

Vitamin D: 25(OH)D {#Sec9}
------------------

Vitamin D insufficiency/deficiency is a global health pandemic, more common in patients in nursing homes and inpatients than patients in the community or outpatients \[[@CR26]\]. The older person is most vulnerable to COVID-19 and death \[[@CR9], [@CR13]\]. Human dipeptidyl peptidase-4 receptor (DPP-4/CD26) binding has recently been shown to interact with the S1 domain of the COVID-19 spike glycoprotein, suggesting that it may be an important virulence factor in SARS-CoV-2 infection \[[@CR27]\]. Of note, DPP-4/CD26 receptor expression has been shown to be significantly reduced in vivo on correction of vitamin D deficiency \[[@CR28]\]. Vitamin D has also been shown to reduce IL-6 production in monocytes \[[@CR29]\]. This evidence provides a rationale for supplementing COVID-19-positive patients with vitamin D \[[@CR30]\].

To conclude, this test menu covers the requirements to manage and assist prognostication of COVID-19 patients in hospital. Given the rapidity with which these patients can deteriorate, we recommend regular testing with vigilance paid to the rate and trajectory of change in each of these parameters.
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